Clinical Trial Update: APC8015 and Bevacizumab in Treating Patients With Prostate Cancer [Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 2 study evaluating APC8015 in combination with bevacizumab for prostate cancer. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• APC8015
• Bevacizumab (bevacizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED